Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Philadelphia Chromosome 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Specimen Handling 15Biopsy 14fludarabine 12Cytarabine 11Cyclophosphamide 11fludarabine phosphate 10X-Rays 9Whole-Body Irradiation 9venetoclax 8Magnetic Resonance Spectroscopy 8Injections 8asciminib 7Azacitidine 7Nuclear Medicine Department, Hospital 6Mycophenolic Acid 6Busulfan 6decitabine and cedazuridine drug combination 5Tacrolimus 5Phantoms, Imaging 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Cyclosporine 5CPX-351 5ruxolitinib 4ivosidenib 4Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Idarubicin 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
bosutinib × Myeloid × 30 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡